Trial Profile

A Phase I Trial of RAD001 (Everolimus) and Avastin(R) (Bevacizumab) in Children With Recurrent Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Everolimus (Primary)
Indications Bone cancer; Brain cancer; CNS cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions
Acronyms RADBEV

Most Recent Events

22 Jan 2020 Results published in the Cancer
13 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com